CA2257898A1 - Utilisation de derives aminothiolesters dans le domaine pharmaceutique - Google Patents

Utilisation de derives aminothiolesters dans le domaine pharmaceutique

Info

Publication number
CA2257898A1
CA2257898A1 CA002257898A CA2257898A CA2257898A1 CA 2257898 A1 CA2257898 A1 CA 2257898A1 CA 002257898 A CA002257898 A CA 002257898A CA 2257898 A CA2257898 A CA 2257898A CA 2257898 A1 CA2257898 A1 CA 2257898A1
Authority
CA
Canada
Prior art keywords
aminothiolester
pharmaceutics
derivatives
pharmaceutical composition
trait
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002257898A
Other languages
English (en)
Other versions
CA2257898C (fr
Inventor
Gerard Anthony Quash
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma Research and Development SNC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2257898A1 publication Critical patent/CA2257898A1/fr
Application granted granted Critical
Publication of CA2257898C publication Critical patent/CA2257898C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Utilisation d'au moins un dérivé aminothiolester pour la préparation d'une composition pharmaceutique destinée à lever l'inhibition d'un caractère résistant à l'induction d'apoptose de cellules transformées, ce caractère étant dû au gène bcl2 présent dans ces cellules. La composition pharmaceutique est plus particulièrement destinée à traiter les pathologies choisies parmi les cancers du sein, les lymphomes des cellules B, les leucémies, les neuroblastomes, les adénocarcinomes de la prostate, les prolactinomas et autres adénomes pituitaires.
CA002257898A 1997-04-08 1998-04-08 Utilisation de derives aminothiolesters dans le domaine pharmaceutique Expired - Fee Related CA2257898C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9704283A FR2761606B1 (fr) 1997-04-08 1997-04-08 Utilisation de derives aminothiolesters dans le domaine pharmaceutique
FR97/04283 1997-04-08
PCT/FR1998/000712 WO1998044919A1 (fr) 1997-04-08 1998-04-08 Utilisation de derives aminothiolesters dans le domaine pharmaceutique

Publications (2)

Publication Number Publication Date
CA2257898A1 true CA2257898A1 (fr) 1998-10-15
CA2257898C CA2257898C (fr) 2003-10-21

Family

ID=9505645

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002257898A Expired - Fee Related CA2257898C (fr) 1997-04-08 1998-04-08 Utilisation de derives aminothiolesters dans le domaine pharmaceutique

Country Status (7)

Country Link
US (1) US6028114A (fr)
EP (1) EP0920310A1 (fr)
JP (1) JP3190048B2 (fr)
AU (1) AU724253B2 (fr)
CA (1) CA2257898C (fr)
FR (1) FR2761606B1 (fr)
WO (1) WO1998044919A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994409A (en) 1997-12-09 1999-11-30 U.S. Bioscience, Inc. Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds
US6489312B1 (en) 1999-06-15 2002-12-03 Medimmune Oncology, Inc. Pharmaceutical formulations comprising aminoalkyl phosphorothioates
FR2809727B1 (fr) 2000-05-31 2002-07-26 Galderma Res & Dev Nouveaux composes aminothiolesters, compositions pharmaceutiques et cosmetiques les contenant et utilisations
US7078402B2 (en) 2000-05-31 2006-07-18 Centre National De La Recherche Scientifique (Cnrs) Aminothiol ester compounds, pharmaceutical and cosmetics compositions containing same and uses thereof
US7053072B2 (en) * 2001-05-11 2006-05-30 Medimmune Oncology, Inc. Methods for the administration of amifostine and related compounds
US6916892B2 (en) * 2001-12-03 2005-07-12 Fina Technology, Inc. Method for transitioning between Ziegler-Natta and metallocene catalysts in a bulk loop reactor for the production of polypropylene
FR2983492B1 (fr) * 2011-12-06 2015-10-30 Advanced Biodesign Procede ex vivo de purge tumorale d'un echantillon biologique
FR3047734B1 (fr) * 2016-02-17 2019-09-06 Advanced Biodesign Procede de preparation de composes aminothiolester et leurs sels

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2550189B1 (fr) * 1983-08-04 1986-03-28 Centre Nat Rech Scient Nouveaux derives acetyleniques possedant une activite d'inhibiteurs d'enzyme, leur preparation et leur application comme medicament
FR2728790B1 (fr) * 1994-12-29 1997-01-24 Cird Galderma Composition modulant l'apoptose comprenant du methonial ou tout facteur influencant le taux intracellulaire de methonial

Also Published As

Publication number Publication date
JPH11513048A (ja) 1999-11-09
US6028114A (en) 2000-02-22
JP3190048B2 (ja) 2001-07-16
AU724253B2 (en) 2000-09-14
EP0920310A1 (fr) 1999-06-09
FR2761606B1 (fr) 1999-05-14
AU7339898A (en) 1998-10-30
FR2761606A1 (fr) 1998-10-09
WO1998044919A1 (fr) 1998-10-15
CA2257898C (fr) 2003-10-21

Similar Documents

Publication Publication Date Title
CA2257898A1 (fr) Utilisation de derives aminothiolesters dans le domaine pharmaceutique
FR2752734B1 (fr) Utilisation de retinoides pour la preparation d'un medicament destine a traiter les affections liees a une surexpression de vegf
DZ1958A1 (fr) Composés inhibiteurs de l'enzyme l-lpa compositionpharmaceutiques les composant et procédés pour leur préparation.
DZ2440A1 (fr) Atropisomères de 3-aryl-4(3h)-quinazolinones procédé pour leur préparation et compositions les contenant.
DZ2753A1 (fr) Hydroxamides d'acides (4-arylsulfonylamino)-tétrahydropyranne-4-carboxyliques) procédé pour leur préparation et compositions les contenant.
DZ2217A1 (fr) Dérivés d'imidazole substitués, procédé pour leur préparation et compositions les contenant.
DZ2303A1 (fr) Dérivés d'indazole nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.
TNSN99236A1 (fr) Derives bicycliques substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
TR200101539T2 (tr) Serum glukoz ve trigliserid seviyelerini düşürme yöntemleri.
BR9809112A (pt) Novo processo para preparação de uma substância farmacologicamente ativa
DZ2699A1 (fr) Dérivés d'érythromycine nouveaux procédé et intermédiaires pour préparation et compositions pharmaceutiques les contenant.
AU1663900A (en) Pharmaceutical composition for oral administration designed to prevent misuse atthe expense of a third party
NZ325060A (en) Non peptide indole derivative and their use as antagonists of gonadotropin releasing hormone
ES8706132A1 (es) Un procedimiento para la preparacion de analogos de benzodiazepina
CA2165521A1 (fr) Composition topique contenant un antagoniste de substance p
HK1033308A1 (en) Glucocorticoid-selective anti-inflammatory agents
AU5754696A (en) Treatment of a trabecular meshwork whose cells are subject to inhibition of cell division with non-steroidal anti-inflammatory drugs
AU8528291A (en) Leukotriene b4 antagonists
DZ2188A1 (fr) Dérivés de quinoxalinedone, procédés et intermédiaires pour leur préparation et compositions pharmaceutiques les contenant.
BG104698A (en) Glucocorticoid-selective anti-inflammatory agents
FR2691507B1 (fr) Structure d'etancheite pour une aube pivotante de turbomachine.
FR2771010B1 (fr) Utilisation d'une combinaison d'un inhibiteur de l'enzyme de conversion de l'angiotensine et d'un diuretique pour le traitement des desordres microcirculatoires
CA2245701A1 (fr) Melanges isolables a partir de graines d'eugenia jambolana lamarck, leur preparation et l'utilisation de ces melanges et certains de leurs constituants comme medicaments
BR9914156A (pt) Formulação de 2-metil-tieno-benzodiazepina
FR2772547B1 (fr) Ensemble corps d'electrode/porte-electrode pour torche plasma

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed